Azeez Farooki, MD
Basic profileAzeez Farooki is an Endocrinology/Metabolic physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 103 publications with 4,359 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year202519 payments$14,105
- KYOWA KIRIN, INC.Program year20258 payments$4,214
- BETA BIONICS, INC.Program year202516 payments$646
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.6%Insulin Analog13.3%Humalog Kwikpen U-10030%Lantus Solostar30%Novolog Flexpen19%Tresiba Flextouch U-1009%Toujeo Solostar7%Basaglar Kwikpen U-1006%Part D<11 patientsBiguanide (metformin)11.1%Metformin Hcl67%Metformin Hcl Er34%Part D≥39 patients+ 7 more classes in this area
Cardiovascular
22.1%Statin12.3%Atorvastatin Calcium58%Rosuvastatin Calcium42%Part D≥33 patientsCholesterol absorption inhibitor2.1%Ezetimibe100%Part D<11 patients+ 6 more classes in this area
Hormonal (systemic)
19.5%l-Thyroxine11.9%Levothyroxine Sodium79%Synthroid21%Part D≥45 patientsCalcium-sensing Receptor Agonist2.2%Cinacalcet Hcl100%Part D≥13 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Marc Ladanyi, MD
Memorial Sloan Kettering Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Murray Brennan, MD
Memorial Sloan Kettering Cancer Center
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”